Science
Mechanism of Action
TXA operates by inhibiting the enzyme plasmin, a key mediator in both melanin production and inflammatory responses within the skin. By blocking the plasminogen/plasmin system, it prevents the interaction between melanocytes and keratinocytes, consequently reducing pigment formation. It further mitigates inflammation by decreasing the production of inflammatory mediators like arachidonic acid and prostaglandin, which are known melanocyte stimulators. Additionally, TXA may inhibit PAR-2 activation, reduce tyrosinase activity, and is hypothesized to minimize dermal vasculature in melasma.
Research
Clinical Evidence
High confidence2%
Key findings
- 01 Clinical studies demonstrate that topical concentrations between 2% and 5% effectively reduce hyperpigmentation, prevent dark spots, and mitigate melasma.
- 02 Within this range, a 3% concentration has been shown to improve visible signs of rosacea and strengthen the skin barrier with just two weeks of topical treatment.
- 03 Concentrations exceeding 5% do not offer enhanced benefits for hyperpigmentation and carry an increased risk of irritation.
Transparency
Dusting Analysis
While Tranexamic Acid is generally recognized for its efficacy, formulations containing less than 2% may not deliver the clinically observed benefits for hyperpigmentation, inflammation, or rosacea, potentially serving as a 'dusting' percentage for marketing purposes rather than true therapeutic effect.
The Formula
Formulation
Stability
Tranexamic Acid is highly water-soluble, with optimal efficacy and stability observed in formulations within a pH range of 5.0 to 7.0. It should be incorporated into the water phase of a formulation at temperatures below 50 degrees Celsius to prevent potential degradation.
Conflicts
- Sugars (potential for discoloration)
Safety
Safety Profile
Topical Tranexamic Acid is generally well-tolerated across all skin types, including sensitive and acne-prone skin. However, concentrations above 5% may increase the risk of irritation, dryness, or flakiness, especially during initial use. While the FDA monitors adverse events for cosmetic ingredients, its topical use is not subject to the same pre-market approval as systemic (oral/injectable) medical applications. Patch testing is recommended, and caution should be exercised in individuals with active conditions like eczema, severe acne, or psoriasis, as it could potentially exacerbate them.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Tranexamic Acid is a valuable active ingredient, highly effective in concentrations between 2% and 5% for reducing hyperpigmentation, preventing dark spots and melasma, and soothing inflammation, making it suitable for a wide range of skin types.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources
- droracle.ai ↗
- typology.com ↗
- specialchem.com ↗
- healthline.com ↗
- nih.gov ↗
- letsmakebeauty.com ↗
- dermnetnz.org ↗
- drugs.com ↗
- mayoclinic.org ↗
- fda.gov ↗
- frontiersin.org ↗
- researchgate.net ↗
- tirabeauty.com ↗
- dermatica.co.uk ↗
- chemicalbook.com ↗
- asahikasei-fc.jp ↗
- lktlabs.com ↗
- caymanchem.com ↗
- paulaschoice-eu.com ↗